Kategorie: Genitourinární nádory
Téma: XXIII. Uroonkologie
Číslo abstraktu: XXIII/ 103
Autoři: MUDr. Kateřina Kubáčková; Mgr. Zbyněk Bortlíček; prof. MUDr. Rostislav Vyzula, CSc.; Doc. MUDr. Tomáš Büchler, Ph.D.; RNDr. Tomáš Pavlík, Ph.D.; Doc. MUDr. Jana Prausová, Ph.D., MBA; prof. MUDr. Bohuslav Melichar, Ph.D.; MUDr. Petra Pokorná; MUDr. Zdeněk Linke
The aim of this study was to describe the characteristics and outcomes of a large cohort of patients treated with sorafenib, and to identify predictive factors associated with prognosis. Patient data were obtained from the national Czech registry (RenIS). Data of virtually all Czech patients receiving targeted therapies are entered into this non-interventional post-registration database. Demographics and clinical data, as well as all treatment sequences and clinical outcomes are reported to this registry. A total of 836 patients treated with sorafenib before March 2013 was included in the analysis. Median age was 63 years and 70% were men. Most patients had received prior treatment with cytokines, sunitinib, or both, and sorafenib was the fi rst-line treatment in 15% of patients. Median overall survival and progression-free survival were 21.7 months and 7.5 months, respectively. Cox proportional models identified several parameters associated with poor outcome including time ≤ 1 year from diagnosis to fi rst-line systemic treatment, performance status ≥ 2, low hemoglobin, and LDH > 1.5 times the upper limit of normal. Our data demonstrate that the outcome of real life patients is comparable to the patients enrolled in clinical trials. Prognostic factors identified in the present study were consistent with previously reported models.
Datum přednesení příspěvku: 9. 4. 2015